Fall/Winter 2017
Two medical research pioneers, Ronald T. Borchardt, Ph.D., and Jared Rutter, Ph.D., joined RiverVest’s Scientific Advisory Board. Borchardt is distinguished professor emeritus of Pharmaceutical Chemistry at The University of Kansas-Lawrence, and Rutter is professor and researcher in the Department of Biochemistry at the University of Utah and investigator with the Howard Hughes Medical Institute.
Portfolio News
Allakos, Inc., San Carlos, CA  is a clinical-stage biopharma company developing antibodies to treat severe allergic and other diseases characterized by excess activity of mast cells and eosinophils.
Amplyx Pharmaceuticals, Inc., San Diego, CA,  is a early clinical-stage biopharma company developing novel, broad-spectrum antifungal agents.
Avalyn Pharma, Inc., Seattle, WA, p reviously named Genoa Pharmaceuticals, is a pre-clinical biopharma company developing inhaled approaches to treat severe respiratory disease.
Spruce Biosciences, Inc., San Francisco, CA, is a clinical-stage biopharma company developing novel therapies for rare endocrine disorders.
Tryton Medical, Inc., Durham, NC  is a commercial-stage medical device company marketing stents to treat coronary bifurcation lesions.
VentureMed Group, Toledo, OH is a commercial-stage medical device company marketing devices for vessel preparation in connection with the interventional treatment of peripheral artery disease.
RiverVest Venture Partners®  is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.